Week In Perspective: S&P 500 Finds Support in Messy Week [26-Mar-21]

The S&P 500 went through some mild swings this week with technical and quarter-end rebalancing factors in effect, but it ultimately ended with a 1.6% gain. The Dow Jones Industrial Average (+1.4%) also closed higher, while the Nasdaq Composite (-0.6%) and Russell 2000 (-2.9%) lost ground.

That’s not to downplay the week’s news flow because there were a lot of noteworthy events, but the market just didn’t want to fit into a clean narrative. The 10-yr yield declined seven basis points to 1.66%, but the mega-caps within the consumer discretionary (-0.2%) and communication services (-1.9%) sectors still underperformed.

One day, the market was rallying on positive-sounding macro news, but it sold off into the close for no apparent reason. The one constant was that the S&P 500’s 50-day moving average (3,874) proved once again to be a strong measure of support, as it has over the past 11 months. After the benchmark index slipped below it on Thursday, buyers stepped in and followed through over the remainder of the week. All of the S&P 500’s weekly gain came on Friday.

Nine of the 11 S&P 500 sectors contributed to the advance, and eight rose at least 2.0%, including the real estate sector with a 4.2% gain. The top-weighted information technology sector gained 2.5%.

Reviewing some of the week’s positive-sounding news:

  • President Biden will announce an infrastructure plan next week (reportedly with a price tag of up to $4 trillion).
  • Weekly initial claims declined by 97,000 to 684,000 for its lowest level since last March.
  • More states said they will expand vaccine eligibility.
  • Intel (INTC) announced plans to invest $20 billion to build two semiconductor manufacturing facilities in Arizona.
  • The eurozone reported stronger-than-expected flash March Manufacturing PMIs.

In other developments, Fed Chair Powell and Treasury Secretary Yellen testified before Congress on the CARES Act in a non-event for the market. AstraZeneca’s (AZN) encouraging U.S. vaccine trial data was questioned by an independent panel, but the company confirmed its vaccine was 76% effective against symptomatic COVID-19.

Week in perspective provided by Briefing.com.

This entry was posted in Blog, Investing, Market Commentary by Mike Minter. Bookmark the permalink.

About Mike Minter

Mike develops investment portfolio allocations, handles trading and rebalancing, and conducts research and analysis as a Portfolio Manager and Financial Advisor for the firm. As a perpetual student of investing and the markets, Mike considers himself obsessed with the subject. Mike has earned the CERTIFIED FINANCIAL PLANNER™ (CFP®) and Certified Fund Specialist® designations. He is also an active member of the Houston chapter of the Financial Planning Association (FPA).   Read Mike's Profile HereRead More Articles by Mike

Mike Minter

Mike develops investment portfolio allocations, handles trading and rebalancing, and conducts research and analysis as a Portfolio Manager and Financial Advisor for the firm. As a perpetual student of investing and the markets, Mike considers himself obsessed with the subject. Mike has earned the CERTIFIED FINANCIAL PLANNER™ (CFP®) and Certified Fund Specialist® designations. He is also an active member of the Houston chapter of the Financial Planning Association (FPA).

Read Mike's Profile HereRead More Articles by Mike

Related Posts